EGFR activity addiction facilitates anti-ERBB based combination treatment of squamous bladder cancer
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
EGFR activity addiction facilitates anti-ERBB based combination treatment of squamous bladder cancer
Authors
Keywords
-
Journal
ONCOGENE
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-09-26
DOI
10.1038/s41388-020-01465-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinical Significance of Squamous Differentiation in Urothelial Carcinoma of the Bladder
- (2018) Akinori Minato et al. Cancer Control
- Appropriate Sequence for Afatinib and Cisplatin Combination Improves Anticancer Activity in Head and Neck Squamous Cell Carcinoma
- (2018) Eleonore Longton et al. Frontiers in Oncology
- Efficacy of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone or in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) with low-abundance mutation
- (2018) Xiangtao Yan et al. LUNG CANCER
- Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy
- (2017) Roland Seiler et al. EUROPEAN UROLOGY
- ITIH5 mediates epigenetic reprogramming of breast cancer cells
- (2017) Michael Rose et al. Molecular Cancer
- HER2 and EGFR amplification and expression in urothelial carcinoma occurs in distinct biological and molecular contexts
- (2017) Pontus Eriksson et al. Oncotarget
- The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part B: Prostate and Bladder Tumours
- (2016) Peter A. Humphrey et al. EUROPEAN UROLOGY
- PARTNER: An open-label, randomized, phase 2 study of docetaxel/cisplatin chemotherapy with or without panitumumab as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck
- (2016) Lori J. Wirth et al. ORAL ONCOLOGY
- Fibroblast growth factor receptor (FGFR) alterations in squamous differentiated bladder cancer: a putative therapeutic target for a small subgroup
- (2016) Philipp H. Baldia et al. Oncotarget
- Cato Guldberg and Peter Waage, the history of the Law of Mass Action, and its relevance to clinical pharmacology
- (2015) Robin E. Ferner et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- The mass action equation in pharmacology
- (2015) Terry Kenakin BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- The Role of EGFR Family Inhibitors in Muscle Invasive Bladder Cancer: A Review of Clinical Data and Molecular Evidence
- (2015) Benjamin A. Mooso et al. JOURNAL OF UROLOGY
- Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline Chemotherapy
- (2014) Woonyoung Choi et al. CANCER CELL
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- (2014) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype
- (2014) S. Rebouissou et al. Science Translational Medicine
- Erlotinib Prolongs Survival in Pancreatic Cancer by Blocking Gemcitabine-Induced MAPK Signals
- (2013) K. Miyabayashi et al. CANCER RESEARCH
- EGFR ligands exhibit functional differences in models of paracrine and autocrine signaling
- (2012) Kristy J. Wilson et al. GROWTH FACTORS
- Dual Targeting of the Epidermal Growth Factor Receptor Using the Combination of Cetuximab and Erlotinib: Preclinical Evaluation and Results of the Phase II DUX Study in Chemotherapy-Refractory, Advanced Colorectal Cancer
- (2012) Andrew J. Weickhardt et al. JOURNAL OF CLINICAL ONCOLOGY
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.
- (2012) Ethan Cerami et al. Cancer Discovery
- An EGFR-ERK-SOX9 Signaling Cascade Links Urothelial Development and Regeneration to Cancer
- (2011) S. Ling et al. CANCER RESEARCH
- Clonal architecture of human prostatic epithelium in benign and malignant conditions
- (2011) Nadine T Gaisa et al. JOURNAL OF PATHOLOGY
- Antagonism between Gefitinib and Cisplatin in Non-small Cell Lung Cancer Cells: Why Randomized Trials Failed?
- (2011) Chun-Ming Tsai et al. Journal of Thoracic Oncology
- A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: clinical and pathological results
- (2010) Raj S. Pruthi et al. BJU INTERNATIONAL
- Role of Epidermal Growth Factor Receptor Degradation in Cisplatin-Induced Cytotoxicity in Head and Neck Cancer
- (2010) Aarif Ahsan et al. CANCER RESEARCH
- Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method
- (2010) T.-C. Chou CANCER RESEARCH
- New Strategies in Head and Neck Cancer: Understanding Resistance to Epidermal Growth Factor Receptor Inhibitors
- (2010) L. F. Chen et al. CLINICAL CANCER RESEARCH
- Consensus for EGFR Mutation Testing in Non-small Cell Lung Cancer: Results from a European Workshop
- (2010) Robert Pirker et al. Journal of Thoracic Oncology
- The lack of target specificity of small molecule anticancer kinase inhibitors is correlated with their ability to damage myocytes in vitro
- (2010) Brian B. Hasinoff et al. TOXICOLOGY AND APPLIED PHARMACOLOGY
- Different immunohistochemical and ultrastructural phenotypes of squamous differentiation in bladder cancer
- (2010) Nadine T. Gaisa et al. VIRCHOWS ARCHIV
- Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium
- (2009) Daniel P. Petrylak et al. BJU INTERNATIONAL
- ErbB receptors and signaling pathways in cancer
- (2009) Nancy E Hynes et al. CURRENT OPINION IN CELL BIOLOGY
- Reduced Erlotinib Sensitivity of Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer following Cisplatin Exposure: A Cell Culture Model of Second-line Erlotinib Treatment
- (2008) T. M. Chin et al. CLINICAL CANCER RESEARCH
- Analyzing real-time PCR data by the comparative CT method
- (2008) Thomas D Schmittgen et al. Nature Protocols
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now